Skip directly to content


Community Mobilization: An Assessment of Mechanisms and Barriers at Community-Based and AIDS Service Organizations in Nine U.S. Metropolitan Areas
January 9, 2017 – New Report Shines Spotlight on Need for More Investments in Community Leadership and Mobilization to End HIV as an Epidemic.

The Fair Pricing Coalition Releases New Report Urging Modernization of Existing Laws to Rein in Drug Pricing
December 7, 2016 – The Fair Pricing Coalition announces the release of “Tackling Drug Costs: A 100-Day Roadmap,” an analysis of existing federal statutes and regulations that should be strengthened to dramatically lower the prices of drugs and biologics in the U.S. The report, distributed to the President-elect’s transition team and Congressional leaders, provides a roadmap that can be implemented quickly on the heels of growing bipartisan support for feasible measures to control the skyrocketing costs of prescription medications.

Shortage of Injectable Estrogen a Crisis for Transgender Women
Public health experts call on FDA to better manage drug shortage process.

December 5, 2016―Today, The Fenway Institute of Fenway Health, Callen-Lorde Community Health Center, and Treatment Action Group (TAG) released a policy brief documenting the public health emergency created by a shortage of injectable estrogen, and calling on the U.S. Food and Drug Administration (FDA) to be more proactive in resolving the crisis.

amfAR/TAG Issue Brief: The Cost of Flat Funding for Biomedical Research
August 12, 2013 – “The Costs of Flat Funding for Biomedical Research,” prepared by the Foundation for AIDS Research (amfAR) in collaboration with TAG, examines the declining purchasing value of public funding for health research at the National Institutes of Health (NIH) and the impact this has on public health, scientific progress, US productivity, and US science leadership.

HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development
22 July 2012 - Visit our new website to:

  • Read the report online
  • Download individual chapters as PDFs
  • Browse for specific information by agent

Does Obama’s 2013 Budget Herald the End of PEPFAR?
Devastating Funding Proposal Undermines the Global Fight Against AIDS

tagline Spring 2012 - A sense of disbelief washed over the global AIDS community last month when President Obama unveiled his fiscal year 2013 budget proposal to cut $563 million from the President’s Emergency Plan for AIDS Relief (PEPFAR) program. Cuts of this magnitude could lead to half a million people being denied lifesaving treatment, and countless preventable new infections. Shock and dismay have since given way to frustration; some feel the administration is signaling that an era of U.S. leadership in the global fight against AIDS may be coming to an end.

Letter to President Obama on Proposed FY 2013 Budget Cut to PEPFAR
March 1, 2012 - Dear Mr. President, As representatives of organizations that advocate for an evidence-based and robust response to global AIDS, we respond to your fiscal year 2013 budget request for the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)—the flagship bilateral AIDS program—with shock and dismay. A proposed reduction of more than 10 percent to this lifesaving program is completely inconsistent with your bold leadership statement on World AIDS Day, with its commitment to scale up HIV treatment to an additional two million people by 2013 and prevention of mother to child transmission interventions for an addition 1.5 million pregnant women, to move forward to realize the goal of an AIDS-free generation. A $546 million proposed reduction in the PEPFAR budget will clearly translate into lives lost, scores of preventable infections, and services denied to orphans and vulnerable children.

Obama’s Global, Domestic & HIV Research FY 2013 Budget Backslides on Existing Commitments
Proposed Cuts to President's Emergency Plan for AIDS Relief (PEPFAR) Would Prevent 500,000 People from Starting on Life-saving HIV Treatment
— President’s 2013 Budget Weakens U.S. Leadership on Fighting HIV Globally and Domestically —
NEW YORK, NY —Thursday, 16 February 2012. Treatment Action Group (TAG) is deeply disappointed by President Obama’s proposed cuts to PEPFAR (President’s Emergency Plan for AIDS Relief) and bilateral TB funds, freezing of NIH (National Institutes of Health) research as well as the insufficient attention to the worsening domestic AIDS crisis in the administration's fiscal year 2013 budget plan. “This senselessly harsh budget will directly contribute to millions of preventable illnesses and deaths among people living with HIV, hepatitis C, and TB in the U.S. and around the world.” said Mark Harrington, Executive Director of TAG, “Why does President Obama want to turn his back on the most effective, life-saving global health and development program in history?"

Letter to Secretary Clinton on the Global Fund to Fight AIDS, TB, and Malaria
7 February 2012 - Dear Secretary Clinton, We write to ask for your leadership in ensuring The Global Fund to Fight AIDS, TB, and Malaria is “open for new business,” saving lives through expanding programming in 2012. We ask that you convene an emergency donor meeting in advance of the July International AIDS Conference to re-invigorate the U.S. three-­year commitment of $4 billion and use it to leverage commitments from other donors to the Global Fund. We also urge you and President Obama to use your political leadership — and the bipartisan support for The Global Fund — to achieve the U.S. pledge in 2013 without sacrificing any funding from essential bilateral AIDS, TB, and Malaria programs, which would undermine the game changing targets you and the president set at the end of last year.

Demand Global Fund to Reverse Cancellation of New Programming
2 December, 2011 - The cancellation by the Global Fund to Fight AIDS, TB and Malaria of all new programming until 2014 is unacceptable. This decision will cost lives and cripple international efforts to deliver on health-related goals, breaking promises made to some of the world’s most vulnerable people, and punishing the Global Fund's success of the last ten years.

AIDS Research: Broad Health and Economic Benefits
July 2011 - Investments in health research at the National Institutes of Health (NIH) have paid enormous dividends in the health and well-being of people in the U.S. and around the world. HIV and AIDS research supported by NIH has yielded important recent advances and holds great promise for significantly reducing HIV infection rates and providing more effective treatments for people living with HIV/AIDS.

An Exploratory Analysis of HIV Treatment Research and Development Investments in 2009
July 2011 - The HIV treatment research landscape is changing. Thanks to recent treatment scale-up and prevention science breakthroughs and the new global treatment target of 15 million by 2015, there is real momentum to bring the epidemic under control and ultimately end it. To capitalize on these scientific gains, continued investment and innovation are necessary to prevent new infections, to ensure people currently on treatment are able to continue, and to scale up treatment to reach all those who will benefit from earlier initiation of antiretroviral therapy. This report from TAG, UNAIDS, and the AIDS Vaccine Advocacy Coalition documents $2.46 billion in HIV-related research investments.

Letter to Dr. Fauci to Support HIV and Aging Research
20 September 2010 - The many complications and comorbidities faced by the aging population of HIV positive people in the United States constitute a rapidly growing medical crisis that has been woefully neglected by U.S. research efforts. According to the Centers for Disease Control, more than half of all HIV-positive Americans will be over the age of 50 by or before the year 2015. Although increasing evidence points to an earlier onset of age related conditions in people living with HIV little is known about pathogenesis, or proper methods to screen for, prevent and manage these conditions, or anticipate the infrastructure needed to deliver care and treatment for people suffering from these conditions.

Treatment Action Campaign's letter to Ambassador Gips, U.S. Embassy, South Africa
17 June, 2010 - We call on the U.S. government to provide global leadership to achieve millennium development goal (MDG) 6, including universal access to antiretroviral therapy (ART).

Issue Brief: A Sound Investment: The Multiplier effect of AIDS Research
March 2010- Investments in health research at the National Institutes of Health (NIH) have paid enormous dividends in the health and well-being of people in the U.S. and around the world. HIV and AIDS research supported by NIH has saved and improved the lives of millions and holds great promise for significantly reducing HIV infection rates and providing more effective treatments for those living with HIV/AIDS. Yet years of erratic funding levels for NIH have undermined our nation’s leadership in health research and our scientists’ ability to take advantage of the expand-ing opportunities to advance healthcare. The race to find better treatments and cures for cancer, heart disease, AIDS, and other diseases—and to control global epidemics such as AIDS, tuberculosis, and malaria—depends on robust long-term investment in health research at NIH.

Assessing President Obama’s Response to the Global AIDS Crisis
December 1, 2009, marks President Obama’s first World AIDS Day in the White House and the first World AIDS Day for the newly elected Congress. The time is right for a frank assessment of his first year in the fight against global AIDS as President. This analysis focuses on the funding and policy decisions the Administration has made since taking office in January 2009, and assesses the human impact of those decisions.

The Future of Global Health: Ingredients for a Bold & Effective U.S. Initiative
October, 2009 - Major accomplishments in global health over the last decade demonstrate that adequately resourced programs, focused on achieving specific results, can improve health outcomes for millions and support economic progress. They also show that distinct public health challenges are closely interconnected and that a comprehensive and integrated strategy is needed to ensure that ambitious health goals are met.

Flat-Lined: How Flat NIH Funding Undermines Research on HIV, Tuberculosis, and Viral Hepatitis
May 2009 - The goal of this funding analysis is to provide a comprehensive picture of the current state of U.S. National Institutes of Health (NIH) research investment in HIV/AIDS and three of its most common coinfections—hepatitis B virus (HBV), hepatitis C virus (HCV), and tuberculosis (TB)—after five years of flat funding at the NIH (2004– 2009).

TAG Calls on Obama Administration to Revitalize the World's Fight Against HIV and AIDS
27 April 2009 - Treatment Action Group (TAG), the nation’s only organization focused exclusively on fighting for better treatments, a cure, and a vaccine for AIDS, today welcomed the Obama administration’s nomination of Dr. Eric Goosby as the next Global AIDS Coordinator in the State Department, which administers the President’s Emergency Plan for AIDS Relief (PEPFAR), the world’s largest international HIV/AIDS prevention and treatment program.

Letter to NIAID Director Anthony Fauci Opposing the HVTN 505 Vaccine Trial
April 7, 2009 - TAG has previously expressed opposition to the PAVE100A vaccine trial involving the Vaccine Research Center’s DNA and Ad5 candidate(i). With the recent presentation by Dan Barouch of new macaque challenge data involving a DNA/adenovirus prime-boost regimen at the 2009 Keystone meeting(ii), we now must vociferously oppose the proposed descendant of PAVE100A, the HVTN 505 trial.

For older publications, please go to the publications page.